GeoVax Labs claimed that although the company’s vaccines are currently being studied for HIV prevention, this is the first study using the same products for treatment of persons who already have HIV infection.
GeoVax Labs said that to be eligible for the study, persons should have had a negative HIV test followed by a positive test up to 6 months later, and they should have started drugs to fight HIV within 6 months of being diagnosed.
The study will last up to 77 weeks. All patients are expected to be followed closely for safety and for the ability of the vaccine to elicit protective immune responses in vaccinated participants.
GeoVax Labs added that ARCA worked together with it to design the protocol for the Phase 1 clinical trial. The trial is based on the achievement of post-vaccine viral control in animal studies conducted in recently infected non-human primates at the Yerkes National Primate Research Center, affiliated with Emory University.